Olaparib is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/10/2022|
|Rapid review completed||20/10/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||26/10/2022|
|Pre-submission consultation with Applicant||Scheduled|
|Current Status||Pre-submission consultation Scheduled|